[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356381-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356381-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","phase-i-study-of-bevacizumab-and-temsirolimus-combination-therapy-in-advanced-malignancies-safety-efficacy-and-ovarian-cancer-expansion","Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies - Safety, Efficacy, and Ovarian Cancer Expansion","","Background: Bevacizumab and temsirolimus address angiogenic and mTOR signaling in cancer progression. Methods: A Phase I study enrolled 48 heavily pretreated patients with advanced solid tumors, including an ovarian cancer expansion cohort. Treatment used bevacizumab biweekly plus temsirolimus weekly in a 3+3 design to determine safety, maximum tolerated dose (MTD), and dose-limiting toxicities (DLTs). Exploratory analyses included tumor genomic profiling and dynamic contrast-enhanced MRI (DCE-MRI). Results and Conclusion: The regimen showed acceptable safety with modest activity; overall ORR was 7.3% and clinical benefit rate was 26.8%, with DCE-MRI tumor regression linked to lower ΔKtrans values.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/phase-i-study-of-bevacizumab-and-temsirolimus-combination-therapy-in-advanced-malignancies-safety-efficacy-and-ovarian-cancer-expansion/356381/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/phase-i-study-of-bevacizumab-and-temsirolimus-combination-therapy-in-advanced-malignancies-safety-efficacy-and-ovarian-cancer-expansion/356381.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of this Phase I study of bevacizumab plus temsirolimus?","Question",{"text":63,"@type":64},"To assess safety, determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs), and characterize efficacy in advanced solid tumors, including an ovarian cancer expansion cohort.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the treatment administered and how was dose escalation structured?",{"text":68,"@type":64},"Patients received bevacizumab biweekly plus temsirolimus weekly using a 3+3 dose-escalation design to define MTD based on DLTs.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key efficacy outcomes reported?",{"text":72,"@type":64},"Overall objective response rate (ORR) was 7.3%, with 19.5% achieving stable disease for at least 6 months (clinical benefit rate 26.8%). In the ovarian cohort, ORR was 16.7% and CBR was 33.3%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356381,1790193130,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion  \nSarinaA. Piha-Paul, MD1, *,, Chieh Tseng, PhD1, Emily Thompson, PhD2, R. Jason Stafford, PhD2, Hung Le, PhD1, Lei Kang, SCD1, Siqing Fu, MD, PhD1,, Apostolia Tsimberidou, MD, PhD1,, George Blumenschein, MD3, Jordi Rodon Ahnert, MD, PhD1, John M. Slopis, MD, MPH4,  \nDavid Hong, MD1, Aung Naing, MD1, Funda Meric-Bernstam, MD1,5,6,, Chaan S. Ng, MD7, Shannon Westin, MD8, Anil K. Sood, MD8  \n1Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States  \n2Department of Imaging Physics, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States  \n3Department of Thoracic and Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States  \n4Department of Neuro-Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States 5The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States  \n6Department of Breast Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States 7Department of Abdominal Imaging, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States  \n8Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States  \n*Corresponding author: Sarina A. Piha-Paul, Department of Investigational Cancer Therapeutics, Unit 455, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ([spihapau@mdanderson.org](spihapau@mdanderson.org)) .  \n‡Principal Investigator: Sarina A. Piha-Paul  \nAbstract  \nBackground: Bevacizumab and temsirolimus target angiogenic and mTOR pathways in cancer progression.  \nMethods: This phase I study enrolled 48 heavily pretreated patients with advanced solid tumors, including an ovarian cancer expansion cohort. Patients received bevacizumab biweekly plus temsirolimus weekly in a 3 + 3 design to assess safety, maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) . Exploratory analyses included tumor genomic profiling and dynamic contrast-enhanced MRI (DCE-MRI) .  \nResults: Patients had a median age of 59 and median four prior therapies. Common tumor types were ovarian (27%) and head and neck (15%) . Treatment-related adverse events occurred in 93.8%, with 31.3% ≥grade 3. Five patients experienced DLTs, including grade 3 enteritis, fatigue, bowel obstruction/abdominal ileus/pulmonary embolism, bowel perforation and grade 3/4 elevated liver enzymes. MTD was bevacizumab 10 mg/ kg biweekly plus temsirolimus 20 mg weekly. Overall, objective response rate (ORR) was 7.3% and 19. 5% achieved stable disease ≥6 months (clinical benefit rate [CBR] 26.8%) . In ovarian cohort, ORR was 16.7% and CBR 33.3% . Patients with tumor regression on DCE-MRI had lower ΔKtrans values.  \nConclusion: Combination therapy showed acceptable safety and modest activity. Molecular and imaging findings were exploratory and limited.  \nThese preliminary observations could inform future biomarker studies. ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT01552434)  \nKey words: phase I trial; bevacizumab; temsirolimus; mTOR inhibitor; anti-VEGF.  \nLessons Learned  \n• Bevacizumab plus temsirolimus is feasible, with a defined maximum tolerated dose and a manageable toxicity profile in heavily pretreated patients.  \n• Clinical benefit was observed across multiple tumor types, with durable stable disease in neurofibromatosis type 2, melanoma, breast, ovarian, ","cbCaira7hC4GUVkn","https://ap.wps.com/l/cbCaira7hC4GUVkn","pdf",1938123,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Lessons Learned\n# Discussion","[{\"question\":\"What was the purpose of this Phase I study of bevacizumab plus temsirolimus?\",\"answer\":\"To assess safety, determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs), and characterize efficacy in advanced solid tumors, including an ovarian cancer expansion cohort.\"},{\"question\":\"How was the treatment administered and how was dose escalation structured?\",\"answer\":\"Patients received bevacizumab biweekly plus temsirolimus weekly using a 3+3 dose-escalation design to define MTD based on DLTs.\"},{\"question\":\"What were the key efficacy outcomes reported?\",\"answer\":\"Overall objective response rate (ORR) was 7.3%, with 19.5% achieving stable disease for at least 6 months (clinical benefit rate 26.8%). In the ovarian cohort, ORR was 16.7% and CBR was 33.3%.\"}]","Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies - Safety, Efficacy, and Ovarian Cancer Expansion | PDF",1790125109,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d76fa15e2e5919ac5adfb897e21336cb.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a12ab24426d71f0f0abb40900eb3f1cd.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f41cc08cc96f40a3b888d9d24fe09847.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f29f7ed0a90a170b095da8ac22c6224d.webp",980,1287]